July

General Meeting of november AG on July 21, 2010 in the Mediapark, Cologne.

PROGEN Biotechnik GmbH obtains certification according to DIN EN ISO 13485:2003 and AC:2007 in the area of development, production and marketing of in-vitro diagnostics, diagnostics for research purposes and research reagents.

September

Effective immediately, CE-certified test systems from PROGEN Biotechnik GmbH/ Multimetrix for 2-step Borrelia diagnosis are accepted as routine method in laboratory diagnostics.

October

PROGEN Biotechnik GmbH and MULTIMETRIX GmbH sign a cooperation agreement with Mikrogen GmbH, Munich, in the field of the multiplex technology based on the Luminex platform.

PROGEN Biotechnik GmbH signs an exclusive distribution agreement with Asuragen Inc., USA, for the marketing of Asuragen products for personalized medicine and accompanying diagnostics in the field of oncology and human genetics.

March

PROGEN Biotechnik GmbH sells major assets to AXIS-SHIELD GmbH. Purchase price is EUR 1,2 mio. PROGEN Biotechnik GmbH is now concentrating again on its core business of development, production and marketing of research reagents and in-vitro diagnostics.

May

In cooperation with Prof. Dr. Werner W. Franke, DKFZ (Deutsches Krebsforschungszentrum/ German Cancer Research Center) PROGEN Biotechnik develops new immunological markers for cell-cell contact.

July

The General Meeting on July 15, 2009 resolve relocation to Cologne.

September

Move into new premises in the "Hansaturm", Cologne, one of the first high-rises in Germany.

November

Relocation of company headquarter of november AG from Munich to Cologne.

January

BIOMED Beteiligungsgesellschaft mbH i.L. Freiburg/Brs. is filing for insolvency.

Judgement to appoint Dr. Dirk Zurek as emergency chairman and appointment as CEO of november AG by board of directors.

February

Dismissal of insolvency proceedings of november AG of December 21 due to missing reason for initiation of proceeding (non-solvency, illiquidity).

April

Assignment of participation (51%) in PEQLAB Biotechnology GmbH.

July

Asset deal of IBL Gesellschaft für Immunchemie und Immunbiologie m.b.H. i.L. to Meddens Diagnostics BV by liquidator.

August

Merger of subsidiary company directif GmbH with subsidiary PROGEN Biotechnik GmbH.

October

Resolution of recapitalization at extraordinary general meeting on October 24, 2008.

December

All shares of the identif GmbH (95%) are sold to Recon Technology Europe GmbH, effective December 31, 2008.

Resolution of the ordinary general meeting to move the november AG place of business to Munich.

January

Insolvency plans are presented to the creditors´ meeting.

February

Participations in Attophotonics Biosciences GmbH (10%) and ZAFENA AB (22.4%) are sold.

March

Creditors´ meeting approves insolvency plans on March 12.

April

The Supervisory Board appoints a new Executive Board effective April 1: Dr. Claus Müller (Chairman of the Board), Jürgen Haegele (Chief Financial Officer), Prof. Dr. Dr. Alois Dresel (Research & Development).

Resolution on April 30 in dismissal of insolvency proceedings.

May

The annual general meeting on May 22 passes resolutions on financial measures as prerequisite for the consolidation of the group, i.e. a capital reduction, a capital increase in form of an investment in kind under exclusion of statutory stock options (contribution of PROGEN Biotechnik GmbH and IBL Gesellschaft für Immunchemie und Immunbiologie i.L.) as well as a cash increase in capital stock with indirect stock options.

September

Contractual resignation of Jürgen Haegele as member of the board of the november AG.

November

<BaFin> Bundesanstalt für Finanzdienstleistungsaufsicht (Federal Financial Supervisory Authority <FFSA>) exempts BIOMED Beteiligungsgesellschaft and 
Dr. Claus Müller from a mandatory offer.

December

Prof. Dr. Dr. Dresel announces his resignation as board member of november AG.

november AG files for insolvency on December 21, 2007.

The 100% subsitidary IBL Gesellschaft für Immunchemie und Immunbiologie files for insolvency.

Resignation of Dr. Claus Müller as chairman of the board of november AG.

March

The corporation points out in its annual report 2005 that short-term capital measures are required to secure corporate financing for fiscal year 2006.

Additionally, it is announced that the responsif GmbH, hitherto financed by the november AG, is working on a fund prospectus designed to finance the responsif GmbH independent from the november AG.

June

The participation in Attophotonics Biosciences GmbH is increased to a total of 10%.

July

The ACGT ProGenomics AG, to 23.88% in the hands of the november AG, files for insolvency.

September

After insolvency assessment, the executive board of the november AG files for insolvency September 26, 2006 at the district court of Fürth – insolvency court – because of insolvency and impending illiquidity.

The subsidiaries identif GmbH and directif GmbH, financed by november AG, as a result also have to file for insolvency due to impending illiquidity. PEQLAB Biotechnologie GmbH is not immediately involved in the insolvency of the parent company.

The patent holders of the Annexin patent withdrew the license resp. sub-license issued to november AG resp. responsif GmbH. As the business model of the responsif GmbH is mainly based on this patent, the loans granted to the responsif GmbH by the november AG are rated as value-less after the license was revoked and, as a result, a complete allowance for loss of investments was made. Change in the board of directors: Dr. Bertling, founder and CEO resigns from office. Reinhard Schüren is appointed new CEO.

December

BIOMED Beteiligungsgesellschaft mbh and Dr. Claus Müller declare their intention to continue the activities of the november group and to guarantee the financing of the companies even during insolvency proceedings.

Insolvency proceedings for the november AG and its insolvent subsidiaries are initiated December 1, 2006.

February

A cooperation agreement is signed with EPIDAUROS Biotechnologie AG. Subject of the agreement is the joint commercialization and marketing of the directif technologies in the area of pharmacogenetics; joint development of customized applications for pharmaceutical companies.

May

november AG acquires 5% of Attophotonics Biosciences GmbH, located in Vienna/Austria.

December

A licence and supply agreement is signed with DuPont Packaging & Industrial Polymers for the worldwide exclusive distribution of brand protection technologies, developed by identif GmbH. Additionally, DuPont acquires 10% share of identif GmbH with a participation agreement.

november AG acquires 5% of Attophotonics Biosciences GmbH, located in Vienna/Austria.

Award

In connection with the Technology Fast 50” Rankings of Deloitte, november AG is awarded as one of the 50 fastest growing German technology companies.

January

Control and profit & loss agreements are signed with identif GmbH and directif GmbH.

Change of company name into november AG.

March

november AG is participating in the foundation of the Swedish ZAFENA AB (22.4% participation); patent transfer of the november technology for self-control of blood coagulation.

August

A participation agreement is signed with ZAFENA AB.

Award

november AG receives an achievement award as one of the “TOP 100 mid-size innovating companies”.

January

Shares are issued in the Prime Standard Segment of the Frankfurter Börse (Germany Stock Exchange – ISIN DE000A0S9N72).

Management buy-out of responsif GmbH.

November

An agreement is signed with Siemens Medical Solutions in the area of diagnostics.

December

100% subsidiaries identif GmbH and directif GmbH are founded; the respective business segments are transferred to these companies.

Award

Achievement award “Bayerischer Innovationspreis” (Bavarian innovation prize).

November

Pooling of R & D activities of three business segments: product and brand protection (identif technologies), diagnostics (directif diagnostic solutions), therapeutical and biological markers (responsif therapeutic solutions).

June

Sales of la fontaine companies.

August

Acquisition of 23.88% of the R & D company ACGT ProGenomics AG to supplement development work in the area of novel drug delivery systems.

November

Licensing of the november technology for self-control of blood coagulation to the Swedish medical technology company Medirox AB.

Award

Runner-up in the “Deutscher Mittelstandspreis” (German prize for small and medium-size businesses), issued by the Bundesministerium für Forschung und Technologie (federal ministry of research & development).

April

Initial public offering of november AG at the Frankfurter Wertpapierbörse (Frankfurt Stock Exchange). First listing April 10 in the segment “Neuer Markt” in the following business areas:

• molecular therapy (drug delivery system, polyome project)
• molecular diagnosis (medical diagnosis, identification techniques, biological markers)
• medical products (novi quick, products sold by the company la fontaine GmbH & Co. KG)

November

Signing of Letter of Interest with Siemens Medical Solutions with the objective of a mutual development of a fully-automated diagnostic device in the PoC segment (Point-of-Care).

December

Acquisition of a 50.94% share in the biotech company PEQLAB Biotechnologie GmbH.

1999

Achievement award: First prize in the 20th “Innovationspreis der Deutschen Wirtschaft” (innovation award of the German economy) in the category “start-ups”.

Change of name into november Aktiengesellschaft für Molekulare Medizin.

1998

Acquisition of the company la fontaine GmbH & Co. KG and la fontaine International Verwaltungs GmbH (100% each).

1997

Change of registered office to Erlangen.

1996

The corporation was founded November 26 as “november Aktiengesellschaft Novus Medicatus Berling, Gesellschaft für Molekulare Medizin” with registered office in Nuremberg..